UNC Stock Overview
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for UNC from our risk checks.
UCB SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €122.25 |
| 52 Week High | €123.20 |
| 52 Week Low | €65.68 |
| Beta | 0.40 |
| 1 Month Change | 6.07% |
| 3 Month Change | 41.13% |
| 1 Year Change | 43.38% |
| 3 Year Change | 54.90% |
| 5 Year Change | 76.25% |
| Change since IPO | 171.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| UNC | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.9% | 3.2% | 1.7% |
| 1Y | 43.4% | -28.2% | 2.3% |
Return vs Industry: UNC exceeded the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: UNC exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| UNC volatility | |
|---|---|
| UNC Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UNC's share price has been volatile over the past 3 months.
Volatility Over Time: UNC's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1925 | 8,767 | Jean-Christophe Tellier | www.ucb.com |
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome.
UCB SA Fundamentals Summary
| UNC fundamental statistics | |
|---|---|
| Market cap | €22.92b |
| Earnings (TTM) | €343.00m |
| Revenue (TTM) | €5.18b |
66.8x
P/E Ratio4.4x
P/S RatioIs UNC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UNC income statement (TTM) | |
|---|---|
| Revenue | €5.18b |
| Cost of Revenue | €1.71b |
| Gross Profit | €3.48b |
| Other Expenses | €3.13b |
| Earnings | €343.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.81 |
| Gross Margin | 67.06% |
| Net Profit Margin | 6.62% |
| Debt/Equity Ratio | 32.1% |
How did UNC perform over the long term?
See historical performance and comparison